Icon Plc (NASDAQ:ICLR) – KeyCorp dropped their Q4 2017 earnings estimates for Icon in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings of $1.39 per share for the quarter, down from their prior estimate of $1.41. KeyCorp currently has a “Buy” rating and a $130.00 target price on the stock.
ICLR has been the topic of several other research reports. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Credit Suisse Group reissued an “outperform” rating and issued a $120.00 target price (up previously from $105.00) on shares of Icon in a report on Monday, October 16th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. SunTrust Banks reissued a “buy” rating and issued a $138.00 target price on shares of Icon in a report on Sunday, October 29th. Finally, Barclays boosted their target price on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $124.91.
Icon (ICLR) opened at $113.97 on Friday. Icon has a 12-month low of $76.46 and a 12-month high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The firm has a market cap of $6,171.70, a P/E ratio of 21.88, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56.
Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 earnings per share.
A number of institutional investors have recently added to or reduced their stakes in ICLR. Schwab Charles Investment Management Inc. raised its stake in Icon by 39.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 16,713 shares of the medical research company’s stock valued at $1,635,000 after purchasing an additional 4,692 shares in the last quarter. Legal & General Group Plc raised its stake in Icon by 35.9% during the second quarter. Legal & General Group Plc now owns 7,592 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 2,006 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Icon by 26.3% during the second quarter. JPMorgan Chase & Co. now owns 37,723 shares of the medical research company’s stock valued at $3,690,000 after purchasing an additional 7,860 shares in the last quarter. Sheaff Brock Investment Advisors LLC purchased a new stake in Icon during the second quarter valued at $208,000. Finally, Seven Eight Capital LP raised its stake in Icon by 750.0% during the second quarter. Seven Eight Capital LP now owns 8,500 shares of the medical research company’s stock valued at $831,000 after purchasing an additional 7,500 shares in the last quarter. 89.66% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Icon Plc (ICLR) Expected to Earn Q4 2017 Earnings of $1.39 Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/21/keycorp-weighs-in-on-icon-plcs-q4-2017-earnings-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Get a free copy of the Zacks research report on Icon (ICLR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.